Antidote
OCTOBER 7, 2022
Different types of clinical studies are designed to investigate potential therapies, medications, and medical devices — and all of these must go through each phase of a clinical trial before they are approved. This means that volunteers who are willing to participate in research studies are essential to medical breakthroughs and the advancement of knowledge surrounding any given condition.
Drug Channels
OCTOBER 7, 2022
Today’s guest post comes from Jon Lanznar, Chief Strategy Officer at vitaCare Prescription Services from GoodRx. Jon discusses vitaCare , a pharmacy services platform acquired by GoodRx earlier this year. vitaCare helps patients understand coverage, identifies available savings opportunities, and facilitates communications between providers and payers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
OCTOBER 7, 2022
This chart shows the companies which have received the most pediatric exclusivities in the past five years. Pediatric exclusivity is granted to drug companies for conducting pediatric studies on their…. The post Pharmaceutical companies with the most ‘Pediatric Exclusivity’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
OCTOBER 6, 2022
According to the Food and Drug Administration (FDA), data should meet certain fundamental elements of quality. Whether they’re recorded on paper or electronically, source data should follow ALCOA-C, an acronym used in clinical research for: . Attributable . Legible . Contemporaneous . Original . Accurate . Complete . If these best practices for source documentation aren’t followed, there is no valid evidence the test article is safe and effective. .
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Antidote
OCTOBER 3, 2022
Complement 3 Glomerulopathy, most commonly shortened to C3G or C3G kidney disease, is a rare type of kidney disease that has only been diagnosed since 2013. “C3” refers to a blood protein that has a vital role in the immune system, and “G” is for the damage to glomeruli in the kidneys.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for TLANDO Tlando is a drug marketed by Antares Pharma Inc and is included in one NDA. It is available from one supplier. There are nine…. The post New patent for Antares Pharma drug TLANDO appeared first on DrugPatentWatch - Make Better Decisions.
The Premier Consulting Blog
OCTOBER 5, 2022
The technology transfer of a manufacturing process to a contract development and manufacturing organization (CDMO) is a key step on the road to developing and commercializing biopharmaceutical products. Successfully executing this step is critical to clearing regulatory expectations, avoiding production delays, and delivering drugs to the market. On the other hand, a failed process technology transfer can lead to problems such as: Delays in starting the first manufacturing batch, due to missing
Antidote
OCTOBER 5, 2022
Clinical trial patient recruitment is an important aspect of medical research, but unfortunately, it is also one of the challenges. There are many regulations surrounding how information about trials can be shared with patients, and because outreach materials must be approved by the Institutional Review Board (IRB) before a campaign launches, planning a recruitment campaign requires a good deal of forward thinking.
Drug Channels
OCTOBER 1, 2022
Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx. Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Click here to learn about the ConnectiveRx Enterprise Data Platform. Read on for Kylie’s insights.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for PROAIR+DIGIHALER Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Advarra
OCTOBER 4, 2022
Clinical trial site selection can make or break a trial’s success before it even begins. The average cost to open an investigator site is estimated at $50,000 1 – a price point compounding quickly when onboarding multiple sites. When you consider around 11% of sites 2 fail to even accrue one participant on a given study, cost savings become a major consideration when evaluating which sites to partner with for a trial.
The Open Targets Blog
OCTOBER 3, 2022
The latest release of the Platform — 22.09 — is now available at platform.opentargets.org. Key points New data, in particular: Open Targets Genetics Genomics England PanelApp Gene burden Probes and drugs New data integrity file , in line with FAIR principles Key stats Metric Count Targets 61,888 Diseases 20,931 Drugs 12,854 Evidence 14,229,684 Associations 7,003,171 Additional statistics are available on the Open Targets Community.
Drug Channels
OCTOBER 1, 2022
Today’s guest post comes from Kylie Hall, Director of Product Management at ConnectiveRx. Kylie explains how new ways of harnessing patient data can transform the way pharmaceutical companies interact with patients and providers—and ultimately help improve adherence. Click here to learn about the ConnectiveRx Enterprise Data Platform. Read on for Kylie’s insights.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for PROAIR+RESPICLICK Proair Respiclick is a drug marketed by Teva Branded Pharm and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Teva Branded drug PROAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
LifeSciVC
OCTOBER 7, 2022
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over adversity to deliver for patients. Spero, dedicated to new solutions for patients with infections, has been no exception. In May, we undertook a difficult, but necessary restructuring after a regulatory setback to our lead program tebipenem.
Drug & Device Law
OCTOBER 7, 2022
We are not the only ones who have pointed out that every new contraceptive for the last fifty years or so has been the subject of litigation and that it is not hard to see how the burden associated with such litigation, even if the manufacturer does well, discourages the development of new options. This dynamic has not been limited to drugs or drug-device combination products.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for AIRDUO+DIGIHALER Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are twenty-six…. The post New patent for Teva Pharm drug AIRDUO DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for ARMONAIR+RESPICLICK Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent for Teva Pharm drug ARMONAIR RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for ARMONAIR+DIGIHALER Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. It is available from one supplier. There are twenty-three…. The post New patent for Teva Pharm drug ARMONAIR DIGIHALER appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for AIRDUO+RESPICLICK Airduo Respiclick is a drug marketed by Teva Pharm and is included in one NDA. It is available from four suppliers. There are sixteen…. The post New patent for Teva Pharm drug AIRDUO RESPICLICK appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for THIOLA+EC Thiola Ec is a drug marketed by Mission Pharmacal Co and is included in one NDA. It is available from one supplier. The generic…. The post New patent for Mission Pharmacal drug THIOLA EC appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for QELBREE Qelbree is a drug marketed by Supernus Pharms and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Supernus Pharms drug QELBREE appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 7, 2022
Annual Drug Patent Expirations for EPSOLAY Epsolay is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from one supplier. There are four…. The post New patent for Galderma Labs drug EPSOLAY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 6, 2022
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 6, 2022
Annual Drug Patent Expirations for AVANDAMET Avandamet is a drug marketed by Sb Pharmco and is included in one NDA. There is one patent protecting this drug and one Paragraph…. The post New patent expiration for Sb Pharmco drug AVANDAMET appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
OCTOBER 5, 2022
This chart shows the pharmaceutical companies with the most elixir dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most elixir dosed drugs…. The post Which pharmaceutical companies have the most elixir dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content